• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个简单的多维指数的推导和验证,纳入运动能力参数,用于特发性肺纤维化的生存预测。

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis.

机构信息

Pulmonary and Critical Care, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.

Service de Pneumologie et Soins Intensifs, Hopital Europeen Georges Pompidou, Paris, France.

出版信息

Thorax. 2023 Apr;78(4):368-375. doi: 10.1136/thoraxjnl-2021-218440. Epub 2022 Mar 24.

DOI:10.1136/thoraxjnl-2021-218440
PMID:35332096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10086452/
Abstract

INTRODUCTION

The gender-age-physiology (GAP) index is an easy-to-use baseline mortality prediction model in idiopathic pulmonary fibrosis (IPF). The GAP index does not incorporate exercise capacity parameters such as 6 min walk distance (6MWD) or exertional hypoxia. We evaluated if the addition of 6MWD and exertional hypoxia to the GAP index improves survival prediction in IPF.

METHODS

Patients with IPF were identified at a tertiary care referral centre. Discrimination and calibration of the original GAP index were assessed. The cohort was then randomly divided into a derivation and validation set and performance of the GAP index with the addition of 6MWD and exertional hypoxia was evaluated. A final model was selected based on improvement in discrimination. Application of this model was then evaluated in a geographically distinct external cohort.

RESULTS

There were 562 patients with IPF identified in the internal cohort. Discrimination of the original GAP index was measured by a C-statistic of 0.676 (95% CI 0.635 to 0.717) and overestimated observed risk. 6MWD and exertional hypoxia were strongly predictive of mortality. The addition of these variables to the GAP index significantly improved model discrimination. A revised index incorporating exercise capacity parameters was constructed and performed well in the internal validation set (C-statistic: 0.752; 95% CI 0.701 to 0.802, difference in C-statistic compared with the refit GAP index: 0.050; 95% CI 0.004 to 0.097) and external validation set (N=108 (C-statistic: 0.780; 95% CI 0.682 to 0.877)).

CONCLUSION

A simple point-based baseline-risk prediction model incorporating exercise capacity predictors into the original GAP index may improve prognostication in patients with IPF.

摘要

简介

性别-年龄-生理指数(GAP)是一种易于使用的特发性肺纤维化(IPF)基线死亡率预测模型。GAP 指数不包含运动能力参数,如 6 分钟步行距离(6MWD)或运动性低氧血症。我们评估了在 GAP 指数中加入 6MWD 和运动性低氧血症是否能改善 IPF 患者的生存预测。

方法

在三级转诊中心确定 IPF 患者。评估原始 GAP 指数的区分度和校准度。然后,将队列随机分为推导和验证集,并评估加入 6MWD 和运动性低氧血症后 GAP 指数的性能。根据区分度的提高选择最终模型。然后在地理位置不同的外部队列中评估该模型的应用。

结果

内部队列中确定了 562 名 IPF 患者。原始 GAP 指数的区分度通过 C 统计量 0.676(95%CI 0.635 至 0.717)进行测量,且高估了观察到的风险。6MWD 和运动性低氧血症对死亡率有很强的预测性。将这些变量加入 GAP 指数显著提高了模型的区分度。构建了一个包含运动能力参数的修订指数,在内部验证集(C 统计量:0.752;95%CI 0.701 至 0.802,与重新拟合 GAP 指数相比的 C 统计量差异:0.050;95%CI 0.004 至 0.097)和外部验证集(N=108(C 统计量:0.780;95%CI 0.682 至 0.877))中表现良好。

结论

一种简单的基于点的基线风险预测模型,将运动能力预测因子纳入原始 GAP 指数,可能会改善 IPF 患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/10086452/663231fdb0b0/thoraxjnl-2021-218440f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/10086452/a8588e0fce7f/thoraxjnl-2021-218440f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/10086452/663231fdb0b0/thoraxjnl-2021-218440f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/10086452/a8588e0fce7f/thoraxjnl-2021-218440f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/10086452/663231fdb0b0/thoraxjnl-2021-218440f02.jpg

相似文献

1
Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis.一个简单的多维指数的推导和验证,纳入运动能力参数,用于特发性肺纤维化的生存预测。
Thorax. 2023 Apr;78(4):368-375. doi: 10.1136/thoraxjnl-2021-218440. Epub 2022 Mar 24.
2
A multidimensional index and staging system for idiopathic pulmonary fibrosis.特发性肺纤维化的多维指数和分期系统。
Ann Intern Med. 2012 May 15;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.
3
External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis.DO-GAP指数在特发性肺纤维化个体生存预测中的外部验证及纵向应用
ERJ Open Res. 2023 May 9;9(3). doi: 10.1183/23120541.00124-2023. eCollection 2023 May.
4
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.6 分钟步行距离是特发性肺纤维化患者死亡率的独立预测因子。
Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.
5
Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study.纤维化间质性肺疾病中低氧血症的发病率及预后意义:一项国际队列研究
Chest. 2021 Sep;160(3):994-1005. doi: 10.1016/j.chest.2021.04.037. Epub 2021 Apr 24.
6
Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.特发性肺纤维化疾病严重度范围的多维评估。
Lung. 2018 Dec;196(6):707-713. doi: 10.1007/s00408-018-0152-4. Epub 2018 Aug 27.
7
IC4: a new combined predictive index of mortality in idiopathic pulmonary fibrosis.IC4:特发性肺纤维化死亡率的新联合预测指标。
Panminerva Med. 2022 Jun;64(2):228-234. doi: 10.23736/S0031-0808.21.04144-6. Epub 2021 Jan 26.
8
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者6分钟步行试验的测试性能特征及最小临床重要差异的验证
Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.
9
Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD.特发性肺纤维化患者肺高血压无创预测工具的建立和验证:模型 FORD 的演进。
J Heart Lung Transplant. 2024 Apr;43(4):547-553. doi: 10.1016/j.healun.2023.11.005. Epub 2023 Nov 17.
10
A modified GAP model for East-Asian populations with idiopathic pulmonary fibrosis.一种针对东亚特发性肺纤维化人群的改良GAP模型。
Respir Investig. 2020 Sep;58(5):395-402. doi: 10.1016/j.resinv.2020.04.001. Epub 2020 Jul 24.

引用本文的文献

1
Development of a Prediction Model for Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Study of the Korea IPF Cohort Registry.特发性肺纤维化急性加重预测模型的开发:韩国特发性肺纤维化队列登记研究
J Korean Med Sci. 2025 Sep 1;40(34):e212. doi: 10.3346/jkms.2025.40.e212.
2
Advanced interstitial lung disease: Evidence-based management and clinical approach.晚期间质性肺疾病:基于证据的管理与临床方法。
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Jun 25;42(2):16206. doi: 10.36141/svdld.v42i2.16206.
3
Validation of the gender, age, physiology model and other prognostic factors in interstitial lung disease patients with systemic autoimmune rheumatic disease.

本文引用的文献

1
Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes.特发性肺纤维化患者严重生理损伤:特征和结局。
Respir Res. 2021 Jan 6;22(1):5. doi: 10.1186/s12931-020-01600-z.
2
Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.慢性肺部疾病成人家庭氧疗。美国胸科学会临床实践指南。
Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-e141. doi: 10.1164/rccm.202009-3608ST.
3
Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017.
系统性自身免疫性风湿疾病所致间质性肺疾病患者的性别、年龄、生理模型及其他预后因素的验证
Sci Rep. 2025 Jul 9;15(1):24691. doi: 10.1038/s41598-025-08484-3.
4
Assessment of lung function and severity grading in interstitial lung diseases (% predicted versus z-scores) and association with survival: A retrospective cohort study of 6,808 patients.间质性肺疾病中肺功能评估及严重程度分级(预测值百分比与z评分)及其与生存率的关联:一项对6808例患者的回顾性队列研究
PLoS Med. 2025 May 29;22(5):e1004619. doi: 10.1371/journal.pmed.1004619. eCollection 2025 May.
5
Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease.一种用于预测间质性肺疾病所致肺动脉高压患者临床恶化的简易风险计算器的推导。
JHLT Open. 2025 Jan 7;7:100206. doi: 10.1016/j.jhlto.2025.100206. eCollection 2025 Feb.
6
Predictive Value of Flow Cytometry Quantification of BAL Lymphocytes and Neutrophils in ILD.流式细胞术对间质性肺疾病患者支气管肺泡灌洗淋巴细胞和中性粒细胞定量分析的预测价值
Cells. 2024 Dec 13;13(24):2066. doi: 10.3390/cells13242066.
7
Consumption of Endogenous Caspase-3 Activates Molecular Theranostic Nanoplatform against Inflammation-Induced Profibrotic Positive Feedback in Pulmonary Fibrosis.内源性半胱天冬酶-3的消耗激活分子诊疗纳米平台以对抗肺纤维化中炎症诱导的促纤维化正反馈。
Adv Sci (Weinh). 2025 Feb;12(6):e2412303. doi: 10.1002/advs.202412303. Epub 2024 Dec 17.
8
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis.改良血细胞GAP模型作为特发性肺纤维化的预后生物标志物
ERJ Open Res. 2024 Jul 29;10(4). doi: 10.1183/23120541.00666-2023. eCollection 2024 Jul.
9
A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis.一种多维分类器,用于支持肺纤维化患者的肺移植转诊。
J Heart Lung Transplant. 2024 Jul;43(7):1174-1182. doi: 10.1016/j.healun.2024.03.018. Epub 2024 Mar 29.
10
Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis.特发性肺纤维化疾病进展的预测性生物标志物
Heliyon. 2023 Dec 11;10(1):e23543. doi: 10.1016/j.heliyon.2023.e23543. eCollection 2024 Jan 15.
2004 年至 2017 年美国特发性肺纤维化的死亡率趋势。
Chest. 2021 Jan;159(1):228-238. doi: 10.1016/j.chest.2020.08.016. Epub 2020 Aug 14.
4
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.特发性肺纤维化患者未接受抗纤维化治疗的预后:一项系统评价。
Eur Respir Rev. 2020 Aug 4;29(157). doi: 10.1183/16000617.0158-2019. Print 2020 Sep 30.
5
Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis.脉搏血氧饱和度可预测特发性肺纤维化的预后。
Respir Investig. 2020 May;58(3):190-195. doi: 10.1016/j.resinv.2019.12.010. Epub 2020 Mar 8.
6
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.欧洲多伙伴特发性肺纤维化注册研究(EMPIRE):验证特发性肺纤维化的长期预后因素。
Respir Res. 2020 Jan 8;21(1):11. doi: 10.1186/s12931-019-1271-z.
7
Comparison of disease progression subgroups in idiopathic pulmonary fibrosis.特发性肺纤维化疾病进展亚组的比较。
BMC Pulm Med. 2019 Nov 29;19(1):228. doi: 10.1186/s12890-019-0996-2.
8
Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.肺功能测定标准化 2019 修订版。美国胸科学会和欧洲呼吸学会官方技术声明。
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.
9
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.特发性肺纤维化的抗纤维化治疗:是时候治疗了。
Respir Res. 2019 Sep 6;20(1):205. doi: 10.1186/s12931-019-1161-4.
10
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.芬兰特发性肺纤维化注册中心患者的人口统计学特征与生存情况
ERJ Open Res. 2019 Jul 8;5(3). doi: 10.1183/23120541.00170-2018. eCollection 2019 Jul.